RxDoctor Payments Data

Karen McGhee

Family · Loxley, ALNPI 1144770389

Payments from drug & device makers

$988in general payments, 2019–2025

Across 35 payments — averaging $28.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$529
  • Abbott$66
  • Novo Nordisk$64
  • Lilly USA, LLC$64
  • AbbVie$55
  • Merck$43
  • plus $167 from 6 others

What the payments were for

  • Food & beverage$988100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$988 in reported general payments places this provider in the 65th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$460
Medicare patients
29
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide52$89,070
FarxigaDapagliflozin Propanediol69$60,860
OzempicSemaglutide42$54,206
JanuviaSitagliptin Phosphate49$53,965
EliquisApixaban21$28,662
LinzessLinaclotide24$26,397
TrulicityDulaglutide15$20,232
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$18,172
RybelsusSemaglutide13$12,054
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,478
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,871
Clonidine16$2,180
Atorvastatin Calcium169$1,819
Albuterol Sulfate HfaAlbuterol Sulfate57$1,738
Omeprazole106$1,610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$64$109,30267 claims
AstraZenecaFarxiga, Breztri Aerosphere$529$79,03289 claims
Novo NordiskOzempic, Rybelsus$64$66,26055 claims
MerckJanuvia$43$53,96549 claims
PfizerEliquis$39$28,66221 claims
AbbVieLinzess$55$26,39724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,415 family providers in Alabama.

Other family in Loxley

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →